CytRx announces Phase II trial of bafetinib in CRPC

Bafetinib (previously known as INNO-406) is a protein kinase inhibitor that targets two different enzymes. The newly announced trial is designed to investigate the potential of bafetinib in the treatment of men with castration-resistant prostate cancer (CRPC) who have progressive disease after treatment with at least one course of chemotherapy. … READ MORE …